Video Library
Patient Education Video Library Welcome to AIM’s melanoma video library. Our extensive collection is organized, below, by subject matter in…
Video Library
Patient Education Video Library Welcome to AIM’s melanoma video library. Our extensive collection is organized, below, by subject matter in…
Side Effect Management Guides
Symptom & Side Effect Management Resource Guides In collaboration with top melanoma oncology specialists, AIM has created comprehensive and current information on the…
Know Your ABCDEs
…your moles, remember the ABCDEs of melanoma. If you notice any of the following, consult your healthcare provider immediately. ABCDEs…
How To Tell Family & Friends
…not told the truth, they will often imagine the worst. Explain simple facts about melanoma: what melanoma is; that you…
Wisconsin
[aim_melanoma_specialist] Find a Specialist University of Wisconsin Carbone Cancer Center * Melanoma Clinic 600 Highland Ave. Madison, WI 53792 1-800-622-8922…
Texas
…1515 Holcombe Blvd. Houston, TX 77030 713-792-6800 mdanderson.org Michael Davies, MD, Ph.D. Chair of Melanoma Medical Oncology Roda Amaria, MD…
Tennessee
…David Portnoy, MD Vanderbilt University Medical Center * Melanoma & Tumor Immunotherapy Program 1301 Medical Center Drive Nashville, TN 37232…
Oregon
…Providers Providence Cancer Center 4805 NE Glisan St #11N-1 Portland, OR 97213 503-215-5696 ProvidenceOregon.org/cancer Brendan Curti, MD, Medical Director, Providence…
Life After Treatment
I’ve Completed Treatment, Now What? For some melanoma patients, the treatment road is short—perhaps surgery to remove the tumor…
Shopping Partners
…and enter AIM at Melanoma. From there you will be directed, depending on whether you want to buy or sell.…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026